

RECORDATI: FILING OF A SOLE SLATE FOR THE RENEWAL OF THE BOARD OF STATUTORY AUDITORS – EXTENSION OF THE DEADLINE AND REDUCTION BY HALF OF THE PARTICIPATION REQUIREMENTS FOR THE FILING

Milan, 4th April 2026 – Pursuant to art. 144-octies, paragraph 2 of Consob’s Regulation 11971/1999 as amended from time to time (the “Issuers’ Regulations”) RECORDATI S.p.A. informs that, as of today, the only slate which has been filed with reference to the appointment of the Board of Statutory Auditors for the period 2026-2028 in the agenda of the Ordinary and Extraordinary General Meeting of the Shareholders 29th April 2026, single call, is the one presented by the majority shareholder Rossini S.à r.l..

Therefore, pursuant to art. 144-sexies, paragraph 5, of the aforementioned Issuers Regulations and also pursuant to the Company’s By-laws, the deadline for filing further slates for the appointment of the Company’s Board of Statutory Auditors is extended to 7th April 2026 (at 6:00 pm), and the minimum threshold for the submission of slates, fixed at 1% of the Company’s share capital having voting rights, is reduced by half, i.e. to 0,5% of the share capital having voting rights.

For the purpose of filing any additional slates, please refer to the notice of call of the aforementioned Shareholders’ General Meeting and to the specific explanatory report of the Board of Directors, already published in accordance with the law and available to the public at the Company’s registered office, on the Company’s website (www.recordati.com, under the section “Investors/Shareholders’ Information”), as well as on the authorised storage mechanism 1INFO (www.1info.it).

Finally, it should be noted that the majority slate for the renewal of the Board of Statutory Auditors submitted by Rossini S. à r.l. and any additional slates filed pursuant to art. 144-sexies, paragraph 5, of the Issuers’ Regulations will be made available to the public by Wednesday 8th April 2026 in the manner set by current legislation.

Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of “unlocking the full potential of life” aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.

Investor Relations

Eugenia Litz
Eugenia.Litz@recordati.com

Gianluca Saletta
saletta.g@recordati.it

Media Relations

Laura Conti
conti.l@recordati.it

Rebecca Kerr
rebecca.kerr@recordati.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office
VIA M. CIVITALI, 1
20148 MILAN, ITALY
TEL. +39 0248787.1
FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up
BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI 00748210150
TAX CODE/VAT NO. 00748210150
MILAN ECONOMIC AND ADMINISTRATIVE INDEX (REA) 401832